Amicus Therapeutics, Inc.  

(Public, NASDAQ:FOLD)   Watch this stock  
Find more results for FOLD
+0.71 (10.33%)
After Hours: 7.57 -0.01 (-0.13%)
Oct 9, 7:59PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 6.88 - 7.71
52 week 5.13 - 18.83
Open 6.97
Vol / Avg. 5.15M/5.34M
Mkt cap 814.91M
P/E     -
Div/yield     -
EPS -0.99
Shares 118.62M
Beta 2.02
Inst. own 101%
Nov 4, 2015
Q3 2015 Amicus Therapeutics Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Oct 2, 2015
Amicus Therapeutics Inc FDA Update
Sep 30, 2015
Amicus Therapeutics Inc at Leerink Partners Rare Disease Roundtable
Aug 5, 2015
Q2 2015 Amicus Therapeutics Inc Earnings Call
Aug 5, 2015
Q2 2015 Amicus Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -5631.21%
Operating margin - -5612.83%
EBITD margin - -5491.59%
Return on average assets -36.49% -40.84%
Return on average equity -50.28% -82.09%
Employees 97 -
CDP Score - -


1 Cedarbrook Dr
CRANBURY, NJ 08512-3618
United States - Map
+1-609-6622000 (Phone)
+1-609-6622001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Company's lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Company's development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Company's programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.

Officers and directors

John F. Crowley J.D. Chairman of the Board, Chief Executive Officer
Age: 48
Bio & Compensation  - Reuters
Bradley L. Campbell President, Chief Operating Officer
Age: 39
Bio & Compensation  - Reuters
William D. Baird III Chief Financial Officer
Age: 43
Bio & Compensation  - Reuters
David Allsop Senior Vice President - International
Bio & Compensation  - Reuters
Dipal Doshi Senior Vice President - Business Planning and Development
Age: 39
Bio & Compensation  - Reuters
Ken Valenzano Ph.D. Senior Vice President - Preclinical Research
Age: 47
Bio & Compensation  - Reuters
Hung Viet Do Chief Scientific Officer
Age: 47
Bio & Compensation  - Reuters
Enrique Dilone Ph.D. Vice President - Technical Operations
Age: 48
Bio & Compensation  - Reuters
Daphne E. Quimi Vice President - Finance, Controller
Age: 49
Bio & Compensation  - Reuters
Mark Baldry Vice President of Global Marketing
Bio & Compensation  - Reuters